FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids. In addition to research opportunities

Sort
E.g., 2013-06-19
E.g., 2013-06-19
Enter a comma separated list of user names.

Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Announces Multi-Target Exosome Assay Validation
Posted by investid on April 12th, 2011

SAN DIEGO - April 12, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc.

Read More
comment 0
Share
Tags:
breast, SAN DIEGO - April 12, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, lymphoma, and colorectal. In July 2010, ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids. In addition to research opportunities, Aethlon Medical plans to test ELLSA as a diagnostic to quantify the therapeutic capabilities of the Aethlon Hemopurifier? to remove immunosuppressive exosomes from the circulatory system of those afflicted with cancer. ESI is now preparing a market survey

ADVERTISE WITH US